The new anti-oncogene clusterin and the molecular profiling of prostate cancer progression and prognosis.
D017209:Apoptosis; D014408:Biomarkers, Tumor; D015152:Blotting, Northern; D015153:Blotting, Western; D002460:Cell Line; D051152:Clusterin; D015331:Cohort Studies; D015536:Down-Regulation; D005500:Follow-Up Studies; D015870:Gene Expression; D016147:Genes, Tumor Suppressor; D006023:Glycoproteins / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D018832:Molecular Chaperones / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy; D012106:Research
D014408:Biomarkers, Tumor; C495242:CLU protein, human; D051152:Clusterin; D006023:Glycoproteins; D018832:Molecular Chaperones; D017430:Prostate-Specific Antigen